Drug & Diagnostic Development 2012（2012年創薬・診断技術開発週間）
2012年8月6-8日 · 米国 ウェスティン サンフランシスコ マーケット ストリート
2011年講演者インタビュー
Leroy Hood, M.D., Ph.D. President Institute for Systems Biology
1. In your opinion, what are the most important scientific advances happening in the individualization/personalization of medicine today?
There are many important advances; the use of family genomic sequencing to identify disease genes; the use of blood biomarkers for early detection and the stratification of disease. The genome sequencing of cancers (and normal blood cells) to assess therapy based on the nature of the mutations observed in the tumors.
2. How are next-generation sequencing and other technologies being used to better understand disease biology and inform healthcare decisions?
Family genome sequencing to identify disease genes. Sequencing of fetal mRNA from the blood of the mother to identify fetal disease genes. Family genome sequencing of families with children having developmental defects. The use of RNA seq to search for mutations in diseased tissues.
3. Is a new paradigm for drug development emerging that will result in better drugs being available more quickly to patients?
Yes the paradigm is the stratification of disease to provide an impedance match between the subtype of a given disease such as breast cancer and the right drug.
Charles R. Cantor, Ph.D. Chief Scientific Officer Sequenom, Inc.
1. In your opinion, what are the most important scientific advances happening in the individualization/personalization of medicine today?
The realization that personalized medicine is no longer an option- it is a necessity
2. How are next-generation sequencing and other technologies being used to better understand disease biology and inform healthcare decisions?
What we call diseases are ill-defined phenotypes. In the future diseases will largely be defined by their molecular phenotypes.
3. Is a new paradigm for drug & diagnostic development emerging that will result in better drugs and diagnostics being available more quickly to patients?
Molecular diagnostics are destined to play a key role in selecting optimal modalities for patient management.
